USCOM LIMITED — AGM Information 2024

Oct 24, 2024

==> picture [140 x 35] intentionally omitted <==

FY24 AGM Presentation ASX: UCM

• MedTech in active growth phase

• Products and markets

• Manufacturing and distribution partnerships

• Rebound ready

• Prepared for strategic restructure

Prof. Rob Phillips Chairman and CEO, Uscom Limited

Oct 25,2024

Uscom Overview

FY25 Outlook

FY24 Results

Milestones

Uscom Markets

Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au

Uscom Vision

“A great company, with great vision, technology and culture, and a great global commercial opportunity”

A Company for the Future

Clinical Mission - To save lives each day in clinical conditions responsible for over 75% of human mortality by demonstrating world leadership in science and creating premium non-invasive cardiovascular pulmonary devices

Commercial Mission – To generate sustainable organic and incremental growth and create a global enterprise of scale, profitability and influence.

Global operations across 6 Australia China

==> picture [34 x 36] intentionally omitted <==

China Hungary Singapore UK

~2000 > 75 IP Over 20 years Sales into 52 >1,200 peer Installed submissions in business countries publications USCOM 1A IP submissions >$30m total receipts Global clinical International peer USCOM 1A units protecting Uscom over 10 years adoption across reviewed US installed globally technology many applications publications

“Medical innovations for the world”

Uscom Overview

FY25 Outlook

FY24 Results

Milestones

Uscom Markets

Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au

Uscom Medical Technology

Future growth from expanding products and global operations

World leading medical technology (ASX:UCM) with global footprint – Sydney, Singapore, Beijing, Budapest, London Delaware

• Cardiovascular and pulmonary devices

• Expanding product portfolio

• Digital technology

• Wireless connectivity

Flagship science and technology in prestige CVP sector. Multiple products with global regulatory, Addressing diseases responsible for >75% of all mortality

1200 publications and multiple global practice guidelines ~2000 USCOM 1A sales into 52 countries

$30m total receipts over 10 years

Foxconn manufacturing partnership to underwrite growth Chinese Foxconn domestic manufacturing, in global operations High margin and >75 IP protected devices

==> picture [4 x 4] intentionally omitted <==

==> picture [140 x 140] intentionally omitted <==

==> picture [109 x 72] intentionally omitted <==

==> picture [119 x 84] intentionally omitted <==

==> picture [116 x 116] intentionally omitted <==

==> picture [97 x 109] intentionally omitted <==

==> picture [45 x 86] intentionally omitted <==

==> picture [83 x 59] intentionally omitted <==

==> picture [145 x 109] intentionally omitted <==

“Saving lives worldwide”

Uscom Overview

FY25 Outlook

FY24 Results

Milestones

Uscom Markets

Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au

Uscom - Revolutionising Hypertension

“Uscom – An innovator and leader in global MedTech”

BP+ Non-invasive central BP monitoring

==> picture [177 x 126] intentionally omitted <==

==> picture [104 x 35] intentionally omitted <==

==> picture [55 x 65] intentionally omitted <==

==> picture [114 x 18] intentionally omitted <==

----- Start of picture text -----

University of Queensland
Institute of Molecular Bioscience
----- End of picture text -----

==> picture [179 x 114] intentionally omitted <==

==> picture [332 x 148] intentionally omitted <==

==> picture [109 x 83] intentionally omitted <==

==> picture [103 x 50] intentionally omitted <==

==> picture [19 x 8] intentionally omitted <==

----- Start of picture text -----

Blue
----- End of picture text -----

Prof Stephane Carlier, European Society of Cardiology

Cardiac Catheter and BP+ measures of central BP are interchangeable

=

==> picture [129 x 181] intentionally omitted <==

==> picture [17 x 8] intentionally omitted <==

----- Start of picture text -----

Red
----- End of picture text -----

==> picture [171 x 128] intentionally omitted <==

==> picture [143 x 103] intentionally omitted <==

==> picture [80 x 47] intentionally omitted <==

==> picture [51 x 12] intentionally omitted <==

----- Start of picture text -----

Uscom
----- End of picture text -----

Uscom Overview

FY25 Outlook

FY24 Results

Milestones

Uscom Markets

Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au

Uscom - Revolutionising Hypertension

“Uscom – An innovator and leader in global MedTech”

==> picture [80 x 47] intentionally omitted <==

Uscom

==> picture [670 x 204] intentionally omitted <==

==> picture [162 x 122] intentionally omitted <==

==> picture [123 x 173] intentionally omitted <==

• The Uscom BP+ is on the International

Space Station for monitoring astronaut physiology

Uscom Overview

FY25 Outlook

FY24 Results

Milestones

Uscom Markets

Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au

Uscom - Revolutionising Preeclampsia

“Uscom – An innovator and leader in global MedTech”

==> picture [524 x 163] intentionally omitted <==

----- Start of picture text -----

17 [th] October 2024
----- End of picture text -----

==> picture [151 x 146] intentionally omitted <==

==> picture [126 x 126] intentionally omitted <==

Prof Herbert Valensise

==> picture [254 x 119] intentionally omitted <==

New multi-centre randomised controlled trial demonstrated that hose treated with USCOM 1A had reduced complications and severity of preeclampsia

USCOM 1A Providing the answers in preeclampsia!

di Pasquo E, Giannubilo SR, Valentini B, etal. The “Preeclampsia and Hypertension Target Treatment” study: a multi-center prospective study to evaluate the effectiveness of the antihypertensive therapy based on maternal hemodynamic findings. Am J Obstet Gynecol MFM2024;6:101368.

Uscom Ltd I FY2024 Annual FY21 Results General Meeting I uscom.com.au

Uscom Overview

FY25 Outlook

FY24 Results

Milestones

Uscom Markets

- Uscom Revolutionising Asthma and COPD

Next generation spirometry

“Hospital in Home” – Asthma, COVID, COPD and Occupational Lung disease Applications - Research/CRO, hospital, clinic, and eHealth home management The SpiroSonic AIR Cycle – Digital data, information, diagnosis and reports generating a cascade of revenue

==> picture [233 x 233] intentionally omitted <==

==> picture [459 x 332] intentionally omitted <==

eHealth Revenue Cascade

• Device sale

• APP Sale

• Software sale

• Cloud storage - Big data

• AI analysis

• Clinician diagnosis

• Prescription

• Report

• System subscription

Digital Home Care Asthma Solution

Home care solution, digital ultrasonic AIR spirometer, BT4 digital connectivity, AIR App and software, Connected to cloud or SpiroReporter.

Revolutionising management of asthma, COPD and COVID

Uscom Ltd I FY2024 Annual FY21 Results General Meeting I uscom.com.au

Uscom Overview

FY25 Outlook

FY24 Results

Milestones

Uscom Markets

- Uscom Divisions and Diseases

Uscom specialised divisions Cardiac Vascular Pulmonary Digital, AI and eHealth

Uscom devices aid treatment of diseases responsible for >75% of all human mortality……..

Brand

Device

Disease and mortality

==> picture [103 x 100] intentionally omitted <==

==> picture [93 x 69] intentionally omitted <==

==> picture [46 x 28] intentionally omitted <==

Uscom

==> picture [60 x 73] intentionally omitted <==

==> picture [71 x 24] intentionally omitted <==

Hear failure – 62% of all deaths were CV related. (Shahim B, Kapelios CJ, Savarese G, Lund LH. Global Public Health Burden of Heart Failure: An Updated Review. Card Fail Rev. 2023 Jul 27;9:e11. doi: 10.15420/cfr.2023.05. PMID: 37547123; PMCID: PMC10398425.)

Hypertension in pregnancy – 140m babies born each year with Hypertensive disease in pregnancy occurring in approximately 15% of those and with nearly 1/3 of deaths during pregnancy having

hypertension. (Ford ND, Cox S, Ko JY, et al. Hypertensive Disorders in Pregnancy and Mortality at Delivery Hospitalization — United States, 2017–2019. MMWR Morb Mortal Wkly Rep 2022;71:585–591. DOI: http://dx.doi.org/10.15585/mmwr.mm7117a1)

Sepsis – 48.9m incidents and 11m deaths – 20% of all global deaths (https://www.who.int/news-room/fact-sheets/detail/sepsis Hypertension – >0.5B sufferers, 18m deaths pa. (https://world-heart-federation.org

Vascular disease – CV disease ~20m deaths pa (https://ourworldindata.org/cardiovascular diseases

Asthma – 262m people affected and 461,000 pa deaths; >1000 per day. (https://globalasthmareport.org/burden/burden). COPD – The third leading cause of deaths worldwide with 3.23m deaths per year (https://www.who.int/news-room/factsheets/detail/chronic-obstructive-pulmonary-disease

“Saving lives worldwide”

Uscom Overview

FY25 Outlook

FY24 Results

Milestones

Uscom Markets

Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au

- Publications Clinical value

Uscom - leader in world cardiovascular and pulmonary science

==> picture [84 x 123] intentionally omitted <==

==> picture [77 x 114] intentionally omitted <==

==> picture [76 x 103] intentionally omitted <==

==> picture [72 x 99] intentionally omitted <==

==> picture [69 x 98] intentionally omitted <==

==> picture [69 x 96] intentionally omitted <==

==> picture [61 x 95] intentionally omitted <==

==> picture [66 x 96] intentionally omitted <==

==> picture [71 x 95] intentionally omitted <==

==> picture [78 x 117] intentionally omitted <==

==> picture [76 x 120] intentionally omitted <==

==> picture [79 x 115] intentionally omitted <==

>1,200

Peer reviewed publications

3

Global Guidelines

Applications

Emergency, Pediatrics, Cardiac transplantation, Hypertension, Electrophysiology, Heart Failure, Emergency transport, Anesthesia, Liver transplantation, ICU, Septic shock, Preeclampsia, Pulmonary hypertension, Exercise physiology, Nurse outreach, Organ procurement, Cancer, Haemodialysis, Neonates, infants, Children adults, elderly etc……..

“Saving lives worldwide”

Uscom Overview

FY25 Outlook

FY24 Results

Milestones

Uscom Markets

Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au

Uscom Devices in World’s Best Hospitals

==> picture [897 x 412] intentionally omitted <==

----- Start of picture text -----

Europe – Slovenjia – Lubiana Asia - China -
University Medical Center LodzEurope - Poland – Chongqing
PERIN Chongqing Asia - China – Beijing
US – Chicago Europe - Italy – Roma Polish Mother’s Memorial Hospital Chilren’s Hospital Fuwai Cardiovascular Hospital
Illinois Children’s
Policlinico Casilino
Hospital Hospital Europe - Chekz Asia - China – Jinan
Europe - Italy – Padova
Rep – Praga Shandong Provincial Hospital
Policlinico - TIN Charles University
US – Pittsburgh Asia - China -
Europe - Italy – Milano
UPMC Children’s IRCCS Policlinico – Europe - Hungary – Chengdu Asia - China – Asia - China – Shanghai
Hospital Pittsburgh Clinica Mangiagalli Budapest West China Shenzhen Children’s Hospital of Shanghai
US – Cincinnatti Szent Istvan & Szenr Women’s and
Cincinnatti Children’s US – Houston Europe - Italy – Milano Laszlo Hospital Children’s Hospital Children’s HospitalShenzhen
HospitaL Texas Children’s Policlinico – Clinica De Asia - China – Shanghai
Hospital Marchi - PS Europe - Switzerland - Geneva FuDan Univeristy HuaShan Hospital
Hopiteaux Universitaire de
Geneve
Europe - Italy – Parma & Firenze Asia - China – Fujian
A.O.U. Parma & A.O.U. Careggi – Europe - Austria – Vienna Fijian Maternal and Children’s Hospital
US – LA US – St Louis Materno Infantile Medical University Asia - China - Guangzhou
Children’s Hospital of Barnes Jewish Hospital Europe - Italy – Trieste Guandong
Europe - Italy – Faenza
Los Angeles Ospedale Burlo Garofolo General Hospital Asia - China – Xiamen
Ospedale Civile – PS –
US – New York Med Urgenza Xiamen University No1 Hospital
Mount Sinai Hospital
New York Europe - Italy – Europe - Italy - – Asia - Indonesia –Jakarta
Vienna
Roma Cipto Mangankusumo
Policlinico Gemelli Medical University Hospital Oceania - Australia –
Brisbane
- TIP
US – Maine Europe - Belgium – Prince Charles Hospital
Maine General Hospital Italy – Monza Genk
Ospedale San Ziekenhuis Oost-
US – Jackson Gerardo - TIN
University of Miami Limburg Hospital Asia - Singapore – Oceania - Australia-
Sydney
Europe - Lithuania – Vilnius S Africa Capetown - KK Women’s and Children’s St George Hospital
UCT University of Capetown
Santariskiu University
South America - Brazil Europe - Netherlands
– Sao Paulo – Maastericht S Africa – Durban Oceania - Australia – Adleaide
Instituta da Crianca, Maastricht University Ethekwinin Hospital and Heart Lyell McEwin Hospital
University Sao Paulo Hospital Centre
----- End of picture text -----

“Saving lives worldwide”

Uscom Overview

FY25 Outlook

FY24 Results

Milestones

Uscom Markets

Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au

FY24 Results

Returning to growth

UCM Total Receipts Trend FY12 – FY25*

==> picture [274 x 259] intentionally omitted <==

==> picture [49 x 47] intentionally omitted <==

==> picture [48 x 48] intentionally omitted <==

==> picture [39 x 39] intentionally omitted <==

$2.52 million $4.21 million 43% Cash on Hand Total Revenue Up sales of products

Building the future

Results

Sale of Goods up 43% on pcp Total Revenue up 33% on pcp

Cash on Hand = $2.52M, up 16%

Uscom’s total revenue over 13 years demonstrating a continuous growth trend only interrupted by geopolitics conflict and international COVID measures (* budgeted).

Uscom Overview

FY25 Outlook

FY24 Results

Milestones

Uscom Markets

Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au

FY24 Results - by Region

A Year of Growth

FY24 Regional Sales Growth

==> picture [817 x 318] intentionally omitted <==

----- Start of picture text -----

Uscom Total Revenue by Region
70 66%
60
50
35% 45% 45%
33% Asia 43%
Europe
Europe
40
Asia
US/Other
US
Australia 30
ROW
7%
Consolidated
20
25%
10
• Global platform for growth
• Hedged for currency and shifting geopolitics 0
• Global reporting, tax, transfer pricing and auditing
-2%
----- End of picture text -----

-10

Uscom Overview

FY25 Outlook

FY24 Results

Milestones

Uscom Markets

Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au

International Brands and eHealth

5 great International Brands across 3 product divisions

==> picture [93 x 76] intentionally omitted <==

Blue Sky Uscom eHealth Ecosystem

Global Medtech Revenues in 2019 ~$500B USD Global Medtech Growth in 2019 5.5% Global Medtech R&D in 2019 ~$31B USD

https://www.statista.com/topics/1702/medical-technology-industry/#dossierContents__outerWrapper

eHealth market expected to grow from USD $59.60 billion in 2020 to USD $206.30 billion in 2027.

% 19.4

eHealth Market forecast to grow at CAGR of 19.4% for the next 7 years

Uscom Group International Brands

	International Brand Branding Sector
	Uscom is an emerging global leader in non- invasive cardiovascular and pulmonary medical devices, developing innovative technologies to solve the challenges of global disease and health care. Cardiovascular Pulmonary
	Non-invasive hemodynamic monitor. USCOM 1A uses advanced Doppler hemodynamics to monitor cardiac blood flow. Cardiovascular USCOM 1A
	Supra-systolic oscillometric central blood pressure monitor BP & Vascular
	The Uscom BP+ Reporter is a patient archiving, analysis and reporting software for use with the Uscom BP+. BP & Vascular Reporter
	SpiroSonic digital ultrasonic spirometers provide ultrasonic spirometry solutions for clinicians and patients. Pulmonary
	spirometry software solution that provides real-time diagnostics, archiving, analysis, trend analysis, configurable reports, export Pulmonary SpiroReporter
	VentiTest is an innovative multi-path digital ultrasonic ventilator calibration solution Pulmonary
	world leading digital technologies into the new cloud based Uscom eHealth Ecosystem E-health Blue Sky Uscom eHealth Ecosystem

Uscom - The Measure of Life

Uscom Overview

FY25 Outlook

FY24 Results

Milestones

Uscom Markets

Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au

Regulatory Approvals

Global Progress

==> picture [687 x 235] intentionally omitted <==

----- Start of picture text -----

Europe
U S C O M 1 A : ✓
B P + : ✓
S p i r o S o n i c : ✓
China, NMPA
U S C O M 1 A :
B P + : ✓✓
S p i r o S o n i c :
US
U S C O M 1 A : ✓
B P + : SE Asia
S p i r o S o n i c : ✓✓ U S C O M 1 A :
B P + :
S p i r o S o n i c : ✓✓✓
Australia
U S C O M 1 A :
B P + : ✓✓
S p i r o S o n i c : ✓
----- End of picture text -----

==> picture [86 x 57] intentionally omitted <==

==> picture [39 x 28] intentionally omitted <==

Regulatory approvals – expensive and unpredictable Increasingly valuable – key to revenue

==> picture [72 x 30] intentionally omitted <==

==> picture [73 x 43] intentionally omitted <==

Uscom Overview

FY25 Outlook

FY24 Results

Milestones

Uscom Markets

Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au

China Connection

China is growing with a mandated focus on advanced medical technology

==> picture [196 x 49] intentionally omitted <==

Manufacturing Partnership

==> picture [891 x 208] intentionally omitted <==

----- Start of picture text -----

COVID Method
Recommended method for
COVID-19 treatment by
Chinese National Health and
Medical Commission
Distribution Partnership
Pre-
2003 2018 2020 2021 2023
USCOM
----- End of picture text -----

==> picture [91 x 12] intentionally omitted <==

----- Start of picture text -----

Uscom China
----- End of picture text -----

Regulatory Approval

SARS-CoV fast track Uscom China established in regulatory approval Beijing

China National High Technology Enterprise (MOST) and AAA Credit Enterprise

300 Chinese publications

installed in >50 infectious disease centres in China >500 units installed nationally >150 national/provincial lectures/collaborations

ED Guidelines for Heart Failure

Uscom Overview

FY25 Outlook

FY24 Results

Milestones

Uscom Markets

Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au

Operational Milestones

H.E. Mr. Graham Fletcher opening Uscom’s manufacturing site in Beijing

H.E. Mr. Graham Fletcher at Uscom’s manufacturing site at Foxconn in Beijing

==> picture [447 x 173] intentionally omitted <==

==> picture [238 x 164] intentionally omitted <==

World leading maternal health experts in Florence for Global Haemodynamics meeting

Uscom education and training in Bali. Indonesia

Beijing Medical Products Authority

• USCOM 1A has received its BMPA approval for domestic manufacture. In partnership with Foxconn are authorised to manufacture USCOM 1A devices at the Foxconn centre in Beijing. This provides advantages in tendering for some hospitals which require domestic manufacture as a condition of purchase.

Manufacturing, distribution and investment

• As Uscom’s products receive regulatory approval the focus is shifting to distribution. We are currently undertaking a number of strategic and innovative next steps to establish partnerships to ensure the fastest and most efficient path to revenue.

Foxconn partnership

• Manufacturing is increasingly a highly regulated and competitive field with scale the pathway to assured supply chain. Uscom’s strategic partnership with Foxconn in China is an important collaboration with the world’s largest manufacturer and provides for outsourcing risk and ensuring supply and upregulation as demand increases.

Uscom Overview

FY25 Outlook

FY24 Results

Milestones

Uscom Markets

Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au

FY25 Drivers

“Uscom – A growing global MedTech”

Growing a global MedTech platform

New evidence – Sepsis, Hypertension, Preeclampsia

New distribution – more management, more regions and more agents

New IP - Constant innovation

New products – Expanded ranges and new technologies

New structure – SE Asian operations and distribution hub

Global Digital Marketing platform – For all products and all regions

Expanded markets – Hedged for geopolitical and economic volatility

==> picture [439 x 288] intentionally omitted <==

----- Start of picture text -----

Europe
US
China
SE Asia
Australia
Growing global markets
----- End of picture text -----

Uscom - The Measure of Life

Uscom Overview

FY25 Outlook

FY24 Results

Milestones

Uscom Markets

Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au

Revenue Growth

==> picture [315 x 139] intentionally omitted <==

----- Start of picture text -----

$21.6B USD
5yr CAGR 4.8%
----- End of picture text -----

==> picture [646 x 139] intentionally omitted <==

----- Start of picture text -----

$1.4B USD $1.3B USD
8yr CAGR 11.2% 5yr CAGR 8.16%
----- End of picture text -----

Products: USCOM 1A

New Products:

• USCOM Maternal

• USCOM v1

• • USCOM v2 • USCOM v3 • USCOM v4 • ...

Software/Consumables:

• CardioCare

• Consumable 1

• • Consumable 2 • Consumable 3 • Consumable 4 • …

Products: BP+ & BP+ Reporter

New Products:

• BP+

• • BP+ v2 • BP+ v3 • ...

==> picture [128 x 88] intentionally omitted <==

Software/Consumables:

• BP+ Reporter

• • Disposable - 10 • BP+ 2 • …

==> picture [104 x 78] intentionally omitted <==

Products: SpiroSonic FLO, SMART, MOBILE, SpiroReporter

New Products:

• SpiroSonic AIR

• • SpiroSonic PRO • SpiroSonic v2 • ...

Software/Consumables:

• SpiroReporter v2

• • SpiroFilter • Disinfectant • SpiroSonic APP – SA1 and SA2 • VentiTest - S

• …

==> picture [140 x 141] intentionally omitted <==

Uscom leading into the future

Uscom Overview

FY25 Outlook

FY24 Results

Milestones

Uscom Markets

Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au

Looking forward

“Vision, technology, culture, and a unique global opportunity” Rapidly growing clinical evidence supporting Uscom devices driving growth into an established and de-risked MedTech enterprise with an expansionary vision providing investors a unique growth opportunities foreseeably.

FY 24 - Achievements

FY25 – Next Steps

• 43% total sales growth

• Regional sales growth

• New products and regulatory

• New IP

• New partnerships – manufacturing and distribution

• SE Asian expansion

• Increasing KOL engagement

• Dealt with unpredictable and volatile markets

• Continue strategic discussions to optimise shareholder value

• Expanded global partnerships in manufacturing and distribution Restructure in SE Asia

• Global distribution

• New IP, R&D and new products

• New marketing initiatives

• Capitalise on life-saving evidence in hypertension, maternal health, sepsis and paediatrics

• Ensure continued high growth

• • Continue strategic discussions to optimise shareholder value

Uscom leading into the future

Uscom Overview

FY25 Outlook

FY24 Results

Milestones

Uscom Markets

Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au

Conclusion

FY24 was a year of resumed growth for Uscom with a 43% rebound in total sales receipts following 10 consecutive years of >20% CAGR pre-COVID.

Uscom has spent the COVID years investing in manufacturing, distribution, partnerships, IP, products, people and research and focusing on the rapid growth region of SE Asia. We now look forward to our global distribution initiatives converting this investment into revenue for investors.

==> picture [176 x 79] intentionally omitted <==

==> picture [452 x 307] intentionally omitted <==

Uscom leading into the future

Corporate Responsibility

==> picture [195 x 61] intentionally omitted <==

==> picture [140 x 35] intentionally omitted <==

Questions and Comments ASX: UCM

Prof. Rob Phillips Chairman and CEO, Uscom Limited

Oct 25,2024

==> picture [140 x 35] intentionally omitted <==

Thank You

ASX: UCM

Prof. Rob Phillips Chairman and CEO, Uscom Limited

Oct 25,2024